Health
Immune dysregulation can affect the efficacy of CAR T therapy in some lymphoma patients – News-Medical.Net
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large…
Chimeric antigen receptor T-cell therapy, or CAR T, has been a breakthrough in the treatment of blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Clinical studies have shown overall response rates of more than 80% with an ongoing response of nearly 40% more than two years after therapy. However, the cellular immunotherapy doesn’t work for every patient.
Moffitt Cancer Center, one of the leading centers for cellular immunotherapy, is researching why some patients…
-
Noosa News17 hours agoTragedy as young footballer found dead on Pacific Motorway, south of Tweed Heads, after cars crash into unoccupied motorbike
-
Noosa News22 hours agoSolo stars to jazz up The J
-
Noosa News19 hours agoSeller disclosure a game changer for Qld – Proctor
-
General22 hours agoAir Canada cancels flights ahead of work stoppage